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Abstract
The TNF-related apoptosis inducing ligand (TRAIL)/TRAIL receptor system participates in crucial steps in immune cell
activation or differentiation. It is able to inhibit proliferation and activation of T cells and to induce apoptosis of neurons and
oligodendrocytes, and seems to be implicated in autoimmune diseases. Thus, TRAIL and TRAIL receptor genes are potential
candidates for involvement in susceptibility to multiple sclerosis (MS). To test whether single-nucleotide polymorphisms
(SNPs) in the human genes encoding TRAIL, TRAILR-1, TRAILR-2, TRAILR-3 and TRAILR-4 are associated with MS susceptibility,
we performed a candidate gene case-control study in the Spanish population. 59 SNPs in the TRAIL and TRAIL receptor genes
were analysed in 628 MS patients and 660 controls, and validated in an additional cohort of 295 MS patients and 233
controls. Despite none of the SNPs withstood the highly conservative Bonferroni correction, three SNPs showing
uncorrected p values,0.05 were successfully replicated: rs4894559 in TRAIL gene, p=9.8610
24, OR=1.34; rs4872077, in
TRAILR-1 gene, p=0.005, OR=1.72; and rs1001793 in TRAILR-2 gene, p=0.012, OR=0.84. The combination of the alleles G/T/
A in these SNPs appears to be associated with a reduced risk of developing MS (p=2.12610
25, OR=0.59). These results
suggest that genes of the TRAIL/TRAIL receptor system exerts a genetic influence on MS.
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Introduction
Multiple Sclerosis (MS) is a chronic, inflammatory, demyelin-
ating and neurodegenerative disease of the Central Nervous
System (CNS). Although its aetiology still remains partially
unknown, MS is thought to arise from complex interactions of
both environmental and genetic factors.
Linkage and association studies demonstrate that MS follows a
polygenic trait, with susceptibility being determined by different
genes, each exerting a relatively moderate effect on overall disease
predisposition [1]. For decades, the only candidate genes
consistently corroborated as influencing MS susceptibility were
encoded within the Major Histocompatibility Complex region
(MHC, HLA) [2–4]. Nevertheless, although data from the latest
large-scale association studies strongly support the dominance of
the HLA locus in genetic susceptibility to MS, they have also led to
substantial progress in unravelling the involvement of other genes
outside the HLA region [5–10].
The tumour necrosis factor (TNF) family genes are strong
candidates for involvement in MS risk because they play
important roles in the interaction between the CNS and the
immune system in both defence and apoptosis of neurons and glial
cells in neuroinflammatory diseases. The TNF-related apoptosis-
inducing ligand (TNFSF10/TRAIL) [11] is a type II transmem-
brane protein belonging to the TNF/nerve growth factor
superfamily [12] capable of inducing apoptosis in susceptible
cells through interaction with its receptors TNFRSF10A/
TRAILR-1 and TNFRSF10B/TRAILR-2. Two other cell-
bound receptors - TNFRSF10C/TRAILR-3 and TNFRSF10D/
TRAILR-4 - and a soluble receptor – Osteoprotegerin - do not
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21766contain functional death domains and act as decoy receptors for
TRAIL.
The TRAIL/TRAIL receptor system might be playing an
important role in the pathogenesis of MS, because of the
expression of apoptosis-mediating and apoptosis-blocking TRAIL
receptors [13], but its exact function is just beginning to unfold.
On one hand, TRAIL might exert a neurotoxic role, as activated
brain macrophages and microglia both express TRAIL [14], and
might interact with TRAIL receptors expressed in neurons,
oligodendrocytes and astrocytes, causing inflammation [15], cell
injury or death [16]. In this sense, it has been reported that both
oligodendrocytes [17], and neurons [14] are susceptible to TRAIL
induced apoptosis.
On the other hand, TRAIL blockade with the administration
of soluble rTRAIL receptor, during the effector phase of MOG-
induced experimental autoimmune encephalomyelitis (EAE),
enhances the formation of inflammatory lesions and the extent
of demyelination in the CNS, and exacerbated EAE, suggesting
that TRAIL may be inhibiting autoimmune inflammation in the
CNS [18]. However, the precise mechanism whereby TRAIL
exerts this mechanism in vivo is not clear. It may inhibit
activation of autoreactive T cells that initiate autoimmune
responses in vitro and in vivo [19] or may induce apoptosis of
inflammatory cells. Recently, it has been reported that activation
of T cells with IL-2 resulted in TRAIL-mediated death of
antigen-specific memory CD8+ T cells and that human T helper
(Th) 1 cell clones are sensitive to TRAIL-induced apoptosis,
whereas Th2 cell lines are not. Whether this is also true in vivo
remains to be clarified [20].
In conclusion, some studies detected anti-inflammatory proper-
ties of TRAIL showing neuroprotective potential, while others
considered it as a mediator of cell damage and inflammatory
response. As TRAIL might be acting in both ways, as a ‘‘double-
edge sword’’ [21,22], TRAIL and TRAIL receptor genes are potential
candidates for involvement in the development of multiple
sclerosis.
The aim of the present study was to examine the potential
role of polymorphisms in the genes encoding TRAIL and its
four surface receptors on MS susceptibility, and to search for
disease-associated combinations of allelic variants in these
polymorphisms.
Results
Genotype frequencies and P values for the 59 polymorphisms
under the four different genetic models were calculated. Three
SNPs were discarded from the study because of technical
problems in the manufacturing process (rs3136597, rs13257094
and rs4242387). Genotype distribution of the remaining 56 SNPs
in controls and MS patients in the original and in the validation
cohorts is shown in Table S1. There were no statistically
significant differences in the genotyping success rate between
cases and controls for any of these markers. Overall, the results
were in Hardy- Weinberg equilibrium after adjustment by the
Benjamini and Hochberg method (Table S2), with the exceptions
of rs3181143 in the TRAIL gene and rs12545733 in the TRAILR-
3 gene, both in MS patients and in controls. Thus, these two
polymorphisms were also discarded from further analyses.
After applying the highly conservative Bonferroni correction for
multiple tests, none of the SNPs analyzed remained significantly
associated with MS risk in the original cohort. However, a total of
six SNPs (rs4894559, rs1001793, rs3924519, rs11779484,
rs4460370 and rs9314261) showed nominally significant associa-
tion in different genetics models, and rs4872077 showed a marked
trend under a recessive model (p=0.052) as shown in Table 1,
hence, these seven SNPs could not be completely dismissed.
The validation with a second cohort of patients and healthy
controls ended with only four out of these seven SNPs showing p
values lower than 0.05. Furthermore, rs9314261 showed the
opposite allele associated in the replication cohort as compared to
the original study, therefore only three associations were
successfully replicated: rs4894559 in TRAIL, rs4872077 in
TRAILR-1 and rs1001793 in TRAILR-2.
When both cohorts were combined in order to increase the
sample size and so, gain statistical power, statistical significance
increased compared to that observed in each cohort separately,
being the lowest p values for each SNPs as follows: rs4894559, risk
allele=A, additive model, p=9.8610
24, OR=1.34; rs4872077,
risk allele=C, recessive model, p=0.005, OR=1.72; and
rs1001793, protective allele=A, additive model, p=0.012,
OR=0.84.
We examined the impact of allelic combinations of the three
previously described SNPs on susceptibility to MS. Analysis of all
possible combinations highlighted rs4894559G, rs4872077T and
rs1001793A as the most relevant combination which was
significantly underrepresented in MS patients and displayed
protective effects for MS. This association was present in the
original cohort (p=2.2610
24, OR=0.59) as well as in the
validation cohort (p=0.0426, OR=0.62). Both cohorts combined
yielded p=2.12610
25, OR=0.59. Distribution of carriers of this
allelic combination in the original cohort, validation cohort and in
the joint analysis is shown in Table 2.
Discussion
This is to the best of our knowledge the first study assessing the
potential role of polymorphisms in the TRAIL receptor genes on MS
susceptibility and also the first one undertaking an in-depth
analysis of the SNPs in the TRAIL gene in this disease.
The TRAIL/TRAIL receptor system has been reported to
participate in crucial steps in immune cell activation, migration,
proliferation and differentiation and it seems to be implicated in a
variety of autoimmune diseases [18,19,23–25]. TRAIL usually
does not induce apoptosis in activated T cells, but it is capable of
directly inhibit proliferation, activation and IFN-c/IL-4 produc-
tion of human T cells via blockade of calcium influx [26] and
induce apoptosis of neurons and oligodendrocytes [16]. Thus,
TRAIL and TRAIL receptor genes are potential candidates for
involvement in the development of multiple sclerosis.
A previous study found an association between rs1131579 in
the 39- u n t r a n s l a t e dr e g i o no fe x o n5i nTRAIL and MS in a
Japanese population [27]. However, we were unable to replicate
this association in the Spanish population, as it was not
polymorphic (frequency of the homozygous common genotype
was 99.9% in controls and 99.9% in MS patients in the joint
Spanish analysis). A previous study identified a highly polymor-
phic region in the TRAIL promoter but could not detect any
associations of the SNPs in this region with MS susceptibility
[28]. In our study, we found seven candidate SNPs associated
with MS risk in the original cohort and carried out a validation
study in a second cohort. This allowed us to confirm the
associations of three of them (rs4894559, risk allele=A;
rs4872077, risk allele=C; and rs1001793, protective allele=A),
and the joint analysis gave us a more reliable measure of the
magnitude of these associations. Furthermore, the study of allele
combinations within these three polymorphisms showed a
stronger association, being the combination of G, T and A
alleles for rs4894559, rs4872077 and rs1001793 respectively, a
TRAIL/TRAIL Receptor System and MS Susceptibility
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may be acting together and may have a synergic effect on MS
susceptibility.
It is unclear whether the lack of validation for the remaining 4
SNPs was due to a lack of statistical power or else they were false
positives, although genotype frequencies seem to support that they
were definitively false positives, with the exception of rs11779484
in TRAILR-1 (Table S1).
The SNP rs4894559 is located in the TRAIL gene, 580
nucleotides upstream of exon 3, SNP rs4872077 is located in the
TRAILR-1 gene, 12 nucleotides downstream of exon 5 and
rs1001793 is located in the TRAILR-2 gene, 92 nucleotides
upstream of exon 2. This latter SNP is a proxy of rs1001792
(r
2=0.91), located 345 nucleotides upstream of exon 2.
All TRAIL apoptotic and decoy receptors are expressed in the
human brain in microvascular endothelial cells [29], oligodendro-
Table 1. Genotype frequencies of the TRAIL and TRAILR significant polymorphisms.
SNP ID Model Original Cohort Validation Cohort Joint Analysis
p value OR (95% C.I.) p value OR (95% C.I.) p value OR (95% C.I.)
rs4894559 L-A [GG=0, GA=1, AA=2] 0.015 1.29 (1.05–1.58) 0.030 1.44 (1.03–2.00) 9.8610
24 1.34 (1.12–1.59)
C[ G Avs. GG] 0.014 1.15 (0.89–1.47) 0.022 1.70 (1.16–2.48) 0.004 1.31 (1.06–1.61)
C[ A Avs. GG] 0.014 2.47 (1.29–4.72) 0.022 0.96 (0.33–2.79) 0.004 1.93 (1.12–3.34)
D [(GA+AA) vs. GG] 0.073 1.24 (0.98–1.58) 0.010 1.62 (1.12–2.35) 0.002 1.36 (1.11–1.66)
R[ A Avs. (GG+GA)] 0.006 2.37 (1.25–4.52) p.0.1 0.034 1.78 (1.03–3.06)
rs4872077 L-A [TT=0, TC=1, CC=2] p.0.1 0.047 1.32 (1.00–1.74) 0.097 1.14(0.98–1.32)
C[ T Cvs. TT] p.0.1 p.0.1 0.021 0.99 (0.81–1.20)
C[ C Cvs. TT] p.0.1 p.0.1 0.021 1.71 (1.15–2.55)
D [(TC+CC) vs. TT] p.0.1 p.0.1 p.0.1
R[ C Cvs. (TT+TC)] 0.052 1.60 (0.99–2.58) 0.060 1.88 (0.95–3.71) 0.005 1.72 (1.17–2.54)
rs11779484 L-A [TT=0, TC=1, CC=2] 0.069 0.75 (0.54–1.02) p.0.1
C[ T Cvs. TT] 0.046 0.69 (0.49–0.96) p.0.1
C[ C Cvs. TT] 0.046 3.01 (0.31–29.03) p.0.1
D [(TC+CC) vs. TT] 0.039 0.71 (0.51–0.99) p.0.1
R[ C Cvs. (TT+TC)] p.0.1 p.0.1
rs1001793 L-A [GG=0, GA=1, AA=2] 0.040 0.84 (0.71–0.99) p.0.1 0.012 0.84 (0.73–0.96)
C[ G Avs. GG] p.0.1 p.0.1 0.035 0.80 (0.66–0.98)
C[ A Avs. GG] p.0.1 p.0.1 0.035 0.73 (0.53–0.99)
D [(GA+AA) vs. GG] 0.074 0.82 (0.65–1.02) 0.064 0.72 (0.51–1.02) 0.012 0.79 (0.65–0.95)
R[ A Avs. (GG+GA)] p.0.1 p.0.1 p.0.1
rs4460370 L-A [CC=0, CT=1, TT=2] 0.026 1.21 (1.02–1.44) p.0.1
C[ C Tvs. CC] 0.048 1.11 (0.88–1.40) p.0.1
C[ T Tvs. CC] 0.048 1.64 (1.10–2.43) p.0.1
D [(CT+TT) vs. CC] p.0.1 p.0.1
R[ T Tvs. (CC+CT)] 0.021 1.56 (1.07–2.27) p.0.1
rs9314261 L-A [GG=0, GA=1, AA=2] 0.026 0.78 (0.62–0.97) p.0.1
C[ G Avs. GG] 0.067 0.74 (0.56–0.97) 0.047 1.30 (0.87–1.95)
C[ A Avs. GG] 0.067 0.72 (0.37–1.40) 0.047 0.43 (0.18–1.04)
D [(GA+AA) vs. GG] 0.020 0.73 (0.57–0.95) p.0.1
R[ A Avs. (GG+GA)] p.0.1 0.035 0.40 (0.17–0.96)
rs3924519 L-A [TT=0, TC=1, CC=2] p.0.1 p.0.1
C[ T Cvs. TT] 0.021 1.06 (0.84–1.34) p.0.1
C[ C Cvs. TT] 0.021 0.61 (0.41–0.90) p.0.1
D [(TC+CC) vs. TT] p.0.1 p.0.1
R[ C Cvs. (TT+TC)] 0.006 0.59 (0.40–0.87) p.0.1
Abbreviations: L-A: Log-Additive model; C: Codominant model; D: Dominant model; R: Recessive model; SNP ID: SNP identification; OR (95% CI): odds ratio with
confidence interval at 95%.
The log-additive model is the equivalent to calculate the odds ratio for the minor allele. The codominant model compared the homozygous genotype for the most
frequent allele to the heterozygous and to the other homozygous genotype. The dominant model compared the homozygous genotype for the most frequent allele to
the combination of the heterozygous and the other homozygous genotype. The recessive model compared a combination of the homozygous for the most frequent
allele and the heterozygous genotypes to the homozygous for the minor allele.
Values in bold indicates p values lower than 0.05; Joint analysis data from non replicated associations are not shown.
doi:10.1371/journal.pone.0021766.t001
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expressed in brain macrophages and infiltrating leukocytes. As
the TRAIL system is characterised by a complex panel of
receptors leading to highly variable effects of TRAIL signalling
dependent on microenvironment, cell type and timing [21], the
interaction of the genes included in this allele combination may
lead to a deregulation of inflammatory pathways. We hypothesize
that the susceptibility conferred by these SNPs could be due to a
change of a protein binding site in the DNA sequence, which may
alter mechanisms involved in alternative splicing, or a change in
the expression levels of TRAIL and its death receptors. These
alterations may affect the TRAIL system, resulting in a more
favourable anti-inflammatory microenvironment. In support of
these mechanisms, some authors have reported that balance
between death and decoy receptors may determine whether a cell
could or could not undergo TRAIL-mediated apoptosis [17,30].
Thus, this triallelic combination might result in target cells, such as
oligodendrocytes, remaining resistant to TRAIL-induced apopto-
sis, which might be one of the putative cytotoxic effector
mechanisms in MS pathogenesis.
In conclusion, the association of these genes with MS risk
supports a biological role for the TRAIL and TRAIL receptor gene
products in the pathogenesis of MS. Therefore, the functional
consequences of these SNPs need to be clarified, as separately they
might be playing only a minor effect on MS susceptibility but the
sum or interaction of multiple risk alleles may represent a key
contributor to the overall MS susceptibility.
Materials and Methods
Ethics Statement
Written informed consent was obtained from patients and
controls. The study was approved by the Institutional Research
Ethics Committees of the respective hospitals (Comisio ´n de E ´tica y
de Investigacio ´n del Hospital Regional Universitario Carlos Haya,
Comite ´E ´tico del Hospital Universitario 12 de Octubre de
Madrid, Comite ´E ´tico de Investigacio ´n Clı ´nica del Hospital
Clı ´nico San Carlos and Comite ´E ´tico de Investigacio ´n Clı ´nica del
Instituto de Investigacio ´n Sanitaria San Carlos).
Study subjects
A total of 628 patients were recruited for the original cohort
through the Multiple Sclerosis unit of Carlos Haya Regional
University Hospital in Malaga, Spain. As controls, 660 sex and
age-matched healthy unrelated subjects were obtained from the
Malaga Blood Bank. For the validation cohort, we selected a total
of 295 patients from the 12 de Octubre University Hospital
(n=59) and San Carlos Clinic Hospital (n=236), both in Madrid,
Spain, and 233 healthy subjects from San Carlos Clinic Hospital.
All patients in both cohorts were Spanish Caucasian individuals
and fulfilled the McDonald criteria [31] for MS diagnosis.
The following demographic and clinical characteristics of the
MS patients were assessed: sex, age, age at onset, clinical form at
onset and at present, disease duration, expanded disability status
scale (EDSS) score, and progression index (current EDSS score/
disease duration). These clinical characteristics of the MS patients
are summarised in Table 3.
SNP identification and selection
54 Tag-SNPs spanning the following genes: TRAIL (mapped at
chromosome 3q26) and its four receptors TRAILR-1, TRAILR-2,
TRAILR-3 and TRAILR-4 (mapped at chromosome 8p21-22),
were selected using the web tool ‘‘SYSNPs’’ (www.sysnps.org).
Flanking regions of 2000 nucleotides upstream and 500 nucleo-
tides downstream were included. A minor allele frequency of at
least 0.1 and a minimum r
2 coefficient of 0.8 were used to select
Tag-SNPs. In addition, we also selected five exonic SNPs in the
TRAIL gene, corresponding to rs6763816 and rs11545817 in exon
1, rs16845759 in exon 2, rs4491934 in exon 3 and rs1131579 in
the 39 UTR of exon 5 (the latter has previously been reported to be
a high risk factor for MS in a Japanese population) [27].
Table 2. Distribution of the carriers of rs4894559G/rs4872077T/rs1001793A.
Original Cohort Validation Cohort Joint Analysis
MS patients Controls MS patients Controls MS patients Controls
GTA carriers 270 (44.3%) 349 (54.1%) 116 (41.7%) 121 (53.8%) 386 (43.5%) 470 (54.0)
Non GTA carriers 339 (55.7%) 296 (45.9%) 162 (58.3%) 104 (46.2%) 501 (56.5%) 400 (46.0)
GTA carriers are made up for subjects with genotypes GG or GA in rs4894559, TT or TC in rs4872077 and AA or AG in rs1001793. Non GTA carriers are made up for
subjects with genotypes AA in rs4894559, CC in rs4872077 and GG in rs1001793.
doi:10.1371/journal.pone.0021766.t002
Table 3. Demographic and clinical characteristics of the 923
MS patients.
Characteristics Original cohort Validation cohort
Gender (%):
Female 431 (68.6%) 192 (65.1%)
Male 197 (31.4%) 103 (34.9%)
Age (years) 43.50611.35 (15–77) 40.6469.00 (19–72)
Mean age at onset (years) 29.5969.73 (4–68) 28.9067.76 (8–53)
Clinical form at onset:
Relapsing 535 (99.4%) 259 (99.6%)
Progressive 3 (0.6%) 1 (0.4%)
Clinical form at present
RR 422 (78.4%) 244 (93.8%)
SP 113 (21.0%) 15 (5.8%)
PP 3 (0.6%) 1 (0.4%)
Mean disease duration (years) 14.568.1 (1–41) 12.1867.28 (0–49)
Current EDSS score 2.8462.26 (0–9) 2.4361.68 (0–7)
Progression index (current
EDSS score/disease duration)
0.2360.24 0.1860.12
Quantitative data are presented as mean 6 standard deviation (minimum–
maximum).
EDSS Expanded disability status scale, PP primary progressive, PR progressive
relapsing, RR relapsing–remitting, SP secondary progressive.
doi:10.1371/journal.pone.0021766.t003
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Genomic DNA was extracted from peripheral blood nucleated
cells using the Genomic DNA Purification KitH (Gentra Systems
Inc, Minneapolis, MN, USA).
All polymorphisms were genotyped using TaqMan assays
(AppliedBiosystems, Inc., Foster City, CA, USA) and the Open-
Array Platform (BioTrove, Woburn, MA, USA) following the
protocols recommended by manufacturers. In short, reactions
were performed in 3072 through-hole arrays under the following
conditions: 93uC for 10 minutes, followed by 50 cycles of 95uC for
45 seconds, 94uC for 13 seconds and 53uC for 134 seconds. The
median DNA concentration used was 50 ng/mL.
Statistical analysis
Statistical analysis was performed using the SPSS software
(version 11.5.1) and the SNPassoc R package (R software version
2.10.0) [32].
Deviations from Hardy-Weinberg Equilibrium were tested
using an exact test as Wigginton et al. [33]. Multiple testing
corrections were carried out using the Benjamini and Hochberg
False Discovery Rate [34].
To test if any individual SNP was associated with MS
susceptibility, genotype frequencies were compared using a
likelihood ratio test under four different genetic models (Codom-
inant, Dominant, Recessive and Additive). P values lower than
0.05 were considered to be statistically significant. Logistic
regression models were used to estimate crude odds ratios (ORs)
and 95% confidence intervals (95% CI). To avoid false-positive
results due to multiple testing we applied the Bonferroni correction
that is robust against positive dependence.
The statistical power was calculated with QUANTO 1.2.4
(http://hydra.usc.edu/gxe). With the original cohort, we had a
91.52% power to detect, at a significance level of 0.05, an OR
effect size of 1.5 when the minor allele frequency was 0.1 under a
log-additive model, decreasing to 50.41% to detect the same effect
at a Bonferroni level (p=0.00089). Power in the validation cohort,
taking into account the results from the original cohort ranged
from 26 to 60% (Table S3).
To study allelic combinations and test their effects on MS
susceptibility we chose those SNPs with a replicated significantly
different distribution between MS patients and controls. Allelic
combinations frequencies were estimated using the Expectation-
Maximization algorithm, and P values and ORs with 95% CI
were calculated with a General Linear Model regression.
Supporting Information
Table S1 Abbreviations: SNP ID, SNP identification; Chr,
chromosome; 1.2, major.minor allele; NSC: Non Synonymous
Coding.
(DOC)
Table S2 Abbreviations: SNP ID, SNP identification; PBH,P
values correct with Benjamini and Hochberg. Departures from
Hardy-Weinberg Equilibrium were tested using an exact test as
Wigginton et al. P values were corrected for multiple testing using
the Benjamini and Hochberg method. Values in bold indicates a
deviation from the Hardy-Weinberg equilibrium. A hyphen
indicates that the Hardy-Weinberg Equilibrium could not be
calculated due to the lack of one or two genotypes.
(DOC)
Table S3 Abbreviations: SNP ID, SNP identification; OR=
odds ratio to be replicated.
(DOC)
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